Stock Ratings / Health Care / DCGO / financials

PIII (24) BMGL (53) CCM (22) EUDA (35) ⌘ Pro Terminal →

DocGo Inc. (DCGO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.25 -9.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.25

DocGo Inc. (DCGO) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $27.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DCGO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DCGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, DocGo Inc. (NASDAQ: DCGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.25 (-9.59% 1D, market cap $27.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DCGO ranks #514 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DCGO compare to PIII and BMGL in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), DCGO carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PIII (P3 Health Partners Inc. (Class A)) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $30.5M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, DCGO leads on earnings multiple (N/A) while DCGO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DCGO?

▼

Per DCGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822359), DocGo Inc. generated $322.2M in revenue (-47.7% YoY), -$196.4M in net income, and $29.9M in free cash flow against $217.1M in total assets and $183.8K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.25 (-1.92%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 9.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DCGO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY DCGO SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 39.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.33-24.2% Next Q

Q2 (-2Q)

Grade D$0.25+12% Next Q

Q3 (-1Q)

Grade D$0.28-10.7% Next Q

Current

Grade D-$0.25-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DCGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DCGO currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.34) and Max Pain ($0.26) forces dealer call-delta covering toward $1.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DCGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DCGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How DCGO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$29.9M (9.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $624.3M

FY24

Rev $616.6M

FY25

Rev $322.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$322.2M	52%	-55.3%	-$196.4M	$29.9M	-45%
FY 2024	$616.6M	52%	4.7%	$13.4M	$66.5M	9.8%
FY 2023	$624.3M	52%	2.4%	$10.0M	-$64.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DCGO)

✓Walkthrough of DCGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DCGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.24%📐 HORIZONTAL RANGE

2026-11-02O $0.28H $0.28L $0.25C $0.25VOL 681.4K

RES: $0.77SUP: $0.20SMA50: $0.34SMA200: $0.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DCGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DCGO Butterfly Map → + Track DCGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -47.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DCGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DCGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DCGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DCGO)

Health Care Rank #514 of 1016 ⚔️ PIII vs DCGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DCGO vs. PIII, BMGL, CCM, EUDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DocGo Inc. (DCGO) ranks #514 by composite RQD confidence (41/100, grade D-) and #815 by equity capitalization ($27.0M). Within this direct 5-issuer industry benchmark cohort, DCGO leads on earnings valuation at N/A trailing P/E, while DCGO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with DCGO at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DCGO ACTIVE DocGo Inc.	D-	41/100	—	—	-35.0%	-9.59%	$27.0M	Benchmark Subject
PIII P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$30.5M	/piii-vs-dcgo →
BMGL Basel Medical Group Ltd	D+	53/100	—	—	—	+6.11%	$36.0M	/bmgl-vs-dcgo →
CCM Concord Medical Services Holdings Limited (Each represents thirty (30) ) (Class A)	E	22/100	—	5.7%	-35.0%	-2.46%	$15.9M	/ccm-vs-dcgo →
EUDA EUDA Health Holdings Limited	D-	35/100	—	43.9%	-35.0%	+14.19%	$46.4M	/euda-vs-dcgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822359

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DocGo Inc. (DCGO) reported GAAP revenue of $322.2M (-47.7% vs. FY2024 revenue of $616.6M , and -48.4% cumulative change since FY2023) , GAAP net income of -$196.4M, operating cash flow of $34.5M, and free cash flow of $29.9M (-55.0% YoY). On the balance sheet, DCGO closed FY2025 with $217.1M in total assets against $183.8K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$322.2M	-$196.4M	$34.5M	$29.9M	$217.1M	$183.8K
FY2024 (FY)	2024-12-31	$616.6M	$13.4M	$70.1M	$66.5M	$455.6M	$5.2K
FY2023 (FY)	2023-12-31	$624.3M	$10.0M	-$64.5M	-$64.5M	—	—

3. DCGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DCGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DCGO compare to PIII and BMGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DCGO?

Where is DCGO trading relative to its 50-day, 200-day, and 52-week technical levels?

DCGO last traded at $0.25 (-9.59% on volume of 1,717,530 shares), positioning the stock -26.47% below its 50-day simple moving average ($0.34) and -56.14% below its 200-day simple moving average ($0.57). Across its 52-week range of $0.24 to $1.16, DCGO sits at the 1.1% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.28).

DCGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is DocGo Inc. (DCGO)?

In FY 2025 (10-K), DCGO converted $322.2M of revenue into a 52% gross margin, 0% operating margin, and $29.9M in free cash flow (9.3% FCF margin).

Direct Sub-Reports: DCGO RQD Cockpit DCGO 12M Forecast DCGO Earnings & Move DCGO Dividends & DRIP DCGO Insiders & 13F DCGO Whale Options DCGO Profit Sankey DCGO News & Why

ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DCGO — DocGo Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:49:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DCGO scores 41 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across its five pillars: the Fundamental Cash Engine scores 8/20 (ROIC -35%; FCF yield 0%), indicating the business is not currently converting capital into returns. Whale 13F Flow scores 11/20 (institutional accumulation and options positioning), the strongest pillar but still below midpoint. Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), the weakest signal in the rating. Macro Regime Fit scores 9/20 (Beta 1.0; sector sensitivity). Forensic Balance Sheet scores 8/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 0.5).

For a prospective investor, the rating points to elevated fundamental and balance-sheet risk. The upside case rests mainly on institutional flow and any recovery in cash generation, which the source data does not establish as already underway. Valuation cannot be framed through earnings multiples because P/E and EV/EBITDA are unavailable in the source data, so the investor would have to weigh a $27.0M market capitalization against a reported FY 2025 net loss and negative ROIC without a standard earnings-based reference point. This is an educational reading of the rating, not personalized financial advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$322.2M	$-178.0M	$-196.4M	N/A	$29.9M	$51.0M	$0.2M
FY 2024	$616.6M	$28.7M	$13.4M	N/A	$66.5M	$89.2M	$0.0M
FY 2023	$624.3M	$15.1M	$10.0M	N/A	$-64.5M	N/A	N/A

Per the SEC financials, revenue fell from $616.6M in FY 2024 to $322.2M in FY 2025, and operating income moved from $28.7M to $-178.0M. Per the market data, operating margin is -55.3%, net margin is -60%, and gross margin is 0%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. Cash of $51.0M against debt of $0.2M is reported for FY 2025, though the forensic Debt/Equity figure is not reconciled to these balances in the source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most material items are debt-related. One report describes DocGo securing up to $102M in term loans at SOFR+7.5% with 4M warrants issued and the Citi revolver terminated. A related Minichart item describes amending the credit facility to raise term loans to $102.5M with the same 4M warrants. Both are rated YELLOW under the source's impact labeling. Remaining items are market-action reports (price ticks toward $0.28 resistance, exhaustion-gap, rectangle-pattern and dark-pool references) from aggregator sources, with no fundamental content beyond price behavior. Per the Butterfly Supply-Chain Graph, no supply chain is mapped and no proprietary signals are listed. Watch items: financing terms at SOFR+7.5%, warrant dilution from the 4M warrants, and the revolver termination.

Open Questions

What drove the revenue decline from $616.6M to $322.2M between FY 2024 and FY 2025, and is it recurring?
What are the covenant and maturity terms of the $102.5M term loans, and how do the 4M warrants affect dilution?
Why does the FY 2023 cash and debt data show N/A, and how does the FCF of $-64.5M reconcile with later years?
How does the profile's $0.0B market capitalization reconcile with the $27.0M figure in market data?
What is the composition of 13F and insider flow behind the 11/20 and 5/20 pillar scores?

DCGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DocGo Inc. (DCGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DCGO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 10h ago

DocGo Inc. (DCGO) Seasonal returns chart

Yahoo Finance UK report covering DocGo Inc. (DCGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

DocGo Secures Up To $102M Term Loans at SOFR+7.5%, Issues 4M Warrants; Terminates Citi Revolver

TradingView report covering DocGo Inc. (DCGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 16h ago

DocGo (DCGO) Ticks Up 3.83% to $0.28 as Shares Hug a Tight Support-Resistance Band - Exhaustion Gap

https://www.siam.in/ report covering DocGo Inc. (DCGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 19h ago

DocGo Inc. (DCGO) Ticks Higher to $0.27 as Buyers Test $0.28 Resistance - Dark Pool Prints

https://www.dars.gov.et/ report covering DocGo Inc. (DCGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Minichart • 1d ago

DocGo Amends Credit Facility, Ups Term Loans to $102.5M, Issues 4M Warrants

Minichart report covering DocGo Inc. (DCGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 3d ago

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DCGO Bull vs. Bear Conversation Board — What's Your Call at $0.25?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DCGO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.24 (-11.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DCGO (D- • RQD 41/100) a Buy at $0.27?

Welcome to the DCGO (DocGo Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.22 (-18.5%)

Spot @ $0.27

Pump the brakes on DCGO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DCGO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless DocGo Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.33 (+22.2%)

Spot @ $0.27

DCGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DCGO, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $0.27 (52-wk range $0.24 - $1.16), any beat on forward guidance forces shorts and underweight funds to chase.